{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:28:48Z","timestamp":1786973328564,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16284-9","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:07:49Z","timestamp":1781132869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review and meta-analysis of treatment-induced hypertension risks from androgen receptor pathway inhibitors in randomized controlled trials for prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Qianqian","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"11","key":"16284_CR1","doi-asserted-by":"publisher","first-page":"103736","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yazgan SC, Yeked\u00fcz E, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024;9(11):103736. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103736.","journal-title":"ESMO Open"},{"issue":"10","key":"16284_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41585-022-00623-z","volume":"19","author":"K Yan","year":"2022","unstructured":"Yan K. Androgen receptor pathway inhibitor combination in prostate cancer. Nat Rev Urol. 2022;19(10):627. https:\/\/doi.org\/10.1038\/s41585-022-00623-z.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"16284_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on Prostate Cancer. Part II-2024 update: treatment of relapsing and metastatic Prostate Cancer. Eur Urol. 2024;86(2):164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"issue":"1","key":"16284_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"16284_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/jnci\/djae155","volume":"116","author":"KS Faraj","year":"2024","unstructured":"Faraj KS, Oerline M, Kaufman SR, et al. Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors. J Natl Cancer Inst. 2024;116(11):1817\u201324. https:\/\/doi.org\/10.1093\/jnci\/djae155.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"16284_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336. https:\/\/doi.org\/10.1016\/j.eururo.2014.07.010.","journal-title":"Eur Urol"},{"issue":"2","key":"16284_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Parizi MK, et al. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28(2):298\u2013308. https:\/\/doi.org\/10.1038\/s41391-024-00886-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"16284_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.012","volume":"6","author":"DP Leong","year":"2024","unstructured":"Leong DP, Guha A, Morgans AK, Niazi T, Pinthus JH. Cardiovascular risk in Prostate Cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6(6):835\u201346. https:\/\/doi.org\/10.1016\/j.jaccao.2024.09.012. Published 2024 Nov 19.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"16284_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccl.2024.09.003","volume":"43","author":"DP Leong","year":"2025","unstructured":"Leong DP, Cirne F, Pinthus JH. Cardiovascular risk in prostate cancer. Cardiol Clin. 2025;43(1):83\u201391. https:\/\/doi.org\/10.1016\/j.ccl.2024.09.003.","journal-title":"Cardiol Clin"},{"issue":"9","key":"16284_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11912-023-01424-2","volume":"25","author":"J Kim","year":"2023","unstructured":"Kim J, Freeman K, Ayala A, Mullen M, Sun Z, Rhee JW. Cardiovascular impact of androgen deprivation therapy: from basic biology to clinical practice. Curr Oncol Rep. 2023;25(9):965\u201377. https:\/\/doi.org\/10.1007\/s11912-023-01424-2.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"16284_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.urolonc.2020.07.004","volume":"38","author":"CS Higano","year":"2020","unstructured":"Higano CS. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. Urol Oncol. 2020;38(12):912\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.004.","journal-title":"Urol Oncol"},{"issue":"11","key":"16284_CR12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3390\/medicina60111727","volume":"60","author":"AB Reiss","year":"2024","unstructured":"Reiss AB, Vasalani S, Albert J, et al. The effect of androgen deprivation therapy on the cardiovascular system in advanced Prostate Cancer. Medicina (Kaunas). 2024;60(11):1727. https:\/\/doi.org\/10.3390\/medicina60111727.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"16284_CR13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.clgc.2023.07.003","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang HM, Jiang Y, et al. Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate cancer: a disproportionality analysis based on the FDA adverse event reporting system (FAERS). Clin Genitourin Cancer. 2023;21(5):594-601.e2. https:\/\/doi.org\/10.1016\/j.clgc.2023.07.003.","journal-title":"Clin Genitourin Cancer"},{"issue":"10323","key":"16284_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"key":"16284_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2021.06.017","volume":"157","author":"N Spetsieris","year":"2021","unstructured":"Spetsieris N, Boukovala M, Alafis I, et al. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na\u00efve prostate cancer. Eur J Cancer. 2021;157:259\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.017.","journal-title":"Eur J Cancer"},{"issue":"5","key":"16284_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(23)00148-1.","journal-title":"Lancet Oncol"},{"key":"16284_CR17","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg"},{"key":"16284_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"4","key":"16284_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(23)00063-3.","journal-title":"Lancet Oncol"},{"issue":"15","key":"16284_CR20","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16284_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"issue":"10336","key":"16284_CR22","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1.","journal-title":"Lancet"},{"issue":"5","key":"16284_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"16284_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011.","journal-title":"Eur Urol"},{"issue":"23","key":"16284_CR25","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2003892.","journal-title":"N Engl J Med"},{"issue":"11","key":"16284_CR26","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"issue":"6","key":"16284_CR27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s12325-022-02140-2","volume":"39","author":"YS Pu","year":"2022","unstructured":"Pu YS, Ahn H, Han W, et al. Enzalutamide in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study. Adv Ther. 2022;39(6):2641\u201356. https:\/\/doi.org\/10.1007\/s12325-022-02140-2.","journal-title":"Adv Ther"},{"issue":"3","key":"16284_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","volume":"78","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, Lin P, Tombal B, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL Trial. Eur Urol. 2020;78(3):347\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.061.","journal-title":"Eur Urol"},{"issue":"2","key":"16284_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ajur.2017.01.002","volume":"4","author":"D Ye","year":"2017","unstructured":"Ye D, Huang Y, Zhou F, et al. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-na\u00efve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian J Urol. 2017;4(2):75\u201385. https:\/\/doi.org\/10.1016\/j.ajur.2017.01.002.","journal-title":"Asian J Urol"},{"issue":"2","key":"16284_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(15)00518-5.","journal-title":"Lancet Oncol"},{"issue":"5","key":"16284_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/iju.13051","volume":"23","author":"Y Sun","year":"2016","unstructured":"Sun Y, Zou Q, Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23(5):404\u201311. https:\/\/doi.org\/10.1111\/iju.13051.","journal-title":"Int J Urol"},{"issue":"18","key":"16284_CR32","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial. J Clin Oncol. 2016;34(18):2098\u2013106. https:\/\/doi.org\/10.1200\/JCO.2015.64.9285.","journal-title":"J Clin Oncol"},{"issue":"2","key":"16284_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7.","journal-title":"Lancet Oncol"},{"issue":"10","key":"16284_CR34","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(12)70379-0.","journal-title":"Lancet Oncol"},{"issue":"13","key":"16284_CR35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"issue":"36","key":"16284_CR36","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271\u201381. https:\/\/doi.org\/10.1200\/JCO-24-01798.","journal-title":"J Clin Oncol"},{"issue":"16","key":"16284_CR37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida LM, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"issue":"1","key":"16284_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40885-019-0116-x","volume":"25","author":"X Zhu","year":"2019","unstructured":"Zhu X, Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens. 2019;25(1):12. https:\/\/doi.org\/10.1186\/s40885-019-0116-x.","journal-title":"Clin Hypertens"},{"issue":"3","key":"16284_CR39","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645\u201353. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.007.","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"16284_CR40","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ejca.2015.06.106","volume":"51","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Verri E, Cossu Rocca M, et al. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Eur J Cancer. 2015;51(14):1970\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2015.06.106.","journal-title":"Eur J Cancer"},{"issue":"2","key":"16284_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14737140.2018.1419871","volume":"18","author":"J Zhu","year":"2018","unstructured":"Zhu J, Liao R, Su C, et al. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. Expert Rev Anticancer Ther. 2018;18(2):193\u20138. https:\/\/doi.org\/10.1080\/14737140.2018.1419871.","journal-title":"Expert Rev Anticancer Ther"},{"key":"16284_CR42","doi-asserted-by":"publisher","first-page":"1386597","DOI":"10.3389\/fonc.2024.1386597","volume":"14","author":"K Chen","year":"2024","unstructured":"Chen K, Wong TH, Tan YG, et al. Cardio-oncology in advanced prostate cancer. Front Oncol. 2024;14:1386597. https:\/\/doi.org\/10.3389\/fonc.2024.1386597.","journal-title":"Front Oncol"},{"issue":"3","key":"16284_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.7150\/jca.32497","volume":"11","author":"R Kumar","year":"2020","unstructured":"Kumar R. Emerging role of glucocorticoid receptor in castration resistant Prostate Cancer: a potential therapeutic target. J Cancer. 2020;11(3):696\u2013701. https:\/\/doi.org\/10.7150\/jca.32497. Published 2020 Jan 1.","journal-title":"J Cancer"},{"issue":"3","key":"16284_CR44","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.5489\/cuaj.7437","volume":"16","author":"L Fleshner","year":"2022","unstructured":"Fleshner L, Berlin A, Hersey K, et al. Time trends of drug-specific actionable adverse events among patients on androgen receptor antagonists: Implications for remote monitoring. Can Urol Assoc J. 2022;16(3):E146\u20139. https:\/\/doi.org\/10.5489\/cuaj.7437.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"16284_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40885-022-00197-3","volume":"28","author":"X Zhu","year":"2022","unstructured":"Zhu X, Wu S. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review. Clin Hypertens. 2022;28(1):14. https:\/\/doi.org\/10.1186\/s40885-022-00197-3. Published 2022 May 15.","journal-title":"Clin Hypertens"},{"issue":"12","key":"16284_CR46","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","volume":"16","author":"S Pandey","year":"2023","unstructured":"Pandey S, Kalaria A, Jhaveri KD, Herrmann SM, Kim AS. Management of hypertension in patients with cancer: challenges and considerations. Clin Kidney J. 2023;16(12):2336\u201348. https:\/\/doi.org\/10.1093\/ckj\/sfad195. Published 2023 Aug 12.","journal-title":"Clin Kidney J"},{"issue":"7","key":"16284_CR47","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s11864-023-01094-z","volume":"24","author":"E Dolmatova","year":"2023","unstructured":"Dolmatova E, Waheed N, Olson BM, Patel SA, Mandawat A. The intersection of prostate cancer and hypertension: a call to action. Curr Treat Options Oncol. 2023;24(7):892\u2013905. https:\/\/doi.org\/10.1007\/s11864-023-01094-z.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"16284_CR48","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639.","journal-title":"JAMA Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16284-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:04:41Z","timestamp":1786971881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16284-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16284"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16284-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"987"}}